SCHEMBL19344087

SCHEMBL19344087

CSc1ncnn2c([C@@H]3O[C@H](CN4CCC(F)(F)C[C@H]4CN4CCCC4)[C@@H](C)[C@H]3OC(C)(C)O)ccc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22434899 0.93 — —
SCHEMBL19344086 0.90 — —
SCHEMBL22435096 0.88 — —
SCHEMBL19344282 0.85 POLRMT (0.30) —
SCHEMBL22434987 0.83 — —
SCHEMBL19344076 0.81 — —
SCHEMBL23584487 0.79 — —
SCHEMBL23584753 0.79 — —
SCHEMBL19344194 0.78 — —
SCHEMBL19343958 0.76 CSNK2A2 (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3426664-B1 SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-06-30 — — EP disclosed
WO-2017153186-A1 SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-14 — — WO disclosed
Send feedback